This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Harrison, B. R Articles by Yackzan, S. Search for Related Content PubMed Articles by Harrison, B. R Articles by Yackzan, S. Social Bookmarking                         What's this?

Docetaxel-induced extravasation injury: a report of three cases

Section of Hematology/Oncology, Veterans Affairs Medical Center, St. Louis, Missouri, Division of Hematology/Oncology, St. Louis University School of Medicine, St. Louis, Missouri

Jennifer R Ketts, PharmD

St. Louis College of Pharmacy, St. Louis, Missouri

Michelle Z Schultz, MD

Section of Hematology/Oncology, Veterans Affairs Medical Center, St. Louis, Missouri, Washington University School of Medicine, St. Louis, Missouri

Susan Yackzan, MSN, RN, AOCN

University of Kentucky Markey Cancer Center, Lexington, Kentucky

Extravasation of chemotherapy drugs may cause serious adverse effects in cancer patients. The clinical course and preferred treatment of some of the newer chemotherapy drugs has not been well described. Three cases of docetaxel extravasation are presented in this report.

The three patients experienced four extravasations of docetaxel and were observed for periods ranging from nine to 19 weeks. Symptoms were fairly similar in all three patients including pain, erythema, edema, pruritus, dyschromia, and hypoesthesia. All three patients received subsequent therapy with docetaxel with no delays in therapy or apparent exacerbation of symptoms. None of these patients had ulceration or visible necrosis. Case 3 received treatment with ice to the second extravasation site. No treatment was administered following the other extravasations.

No recommendations for treating docetaxel extravasation were found. Observations of these three cases suggest that docetaxel is an irritant, but there currently is no evidence to implicate docetaxel as a vesicant. Docetaxel extravasation should be managed conservatively.

Key Words: Extravasation • docetaxel • chemotherapy • vesicant

Journal of Oncology Pharmacy Practice, Vol. 6, No. 3, 122-125 (2000)
DOI: 10.1177/107815520000600306


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?